FrancophonIA/ELRC3.0 huggingface dataset:
English: In pooled data from three trials, 39 patients with relapsed or chemoresistant, bulky disease (single lesion ≥ 10 cm in diameter), low grade or follicular B cell NHL received 375 mg/m2 of rituximab as intravenous infusion weekly for four doses.
Slovenian: Združeni podatki treh preskušanj navajajo, da je 39 bolnikov, pri katerih se je nizko maligni ali folikularni B-celični ne-Hodgkinov limfom ponovil ali pa so bili bolniki neodzivni na kemoterapijo in so imeli obsežno bolezen (ena lezija ≥ 10 cm v premeru), prejelo 4 odmerke po 375 mg/m2 rituksimaba v obliki intravenske infuzije enkrat na teden.
English: For CLL patients whose lymphocyte counts are > 25 x 109/L it is recommended to administer prednisone/prednisolone 100 mg intravenous shortly before infusion with Truxima to decrease the rate and severity of acute infusion reactions and/or cytokine release syndrome.
Slovenian: povezanih z infuzijo, in/ali sindroma sproščanja citokinov priporočljivo intravensko dati 100 mg prednizona/prednizolona malo pred infuzijo zdravila Truxima.
English: They were characterised by pulmonary events and in some cases included rapid tumour lysis and features of tumour lysis syndrome in addition to fever, chills, rigors, hypotension, urticaria, angioedema and other symptoms (see section 4.8).
Slovenian: Značilni zanje so bili pljučni dogodki in v nekaterih primerih hiter razpad tumorja z značilnostmi sindroma razpada tumorja, poleg zvišane telesne temperature, mrzlice, drgetanja,
English: • a complex of symptoms occurring within a few weeks of an infusion of Truxima including allergic like reactions such as rash, itching, joint pain, swollen lymph glands and fever
Slovenian: Zelo redki neželeni učinki (pojavijo se lahko pri 1 od 10.000 bolnikov): skupek simptomov, ki se pojavi v nekaj tednih po prejemu infuzije zdravila Truxima, in vključuje alergijske reakcije, kot so kožni izpuščaji, srbenje, bolečine v sklepih, otekle bezgavke in zvišano telesno temperaturo,
English: For retreatment with Truxima monotherapy for patients who have responded to previous treatment with Truxima monotherapy for relapsed/refractory follicular lymphoma, the recommended dose is: 375 mg/m2 body surface area, administered as an intravenous infusion once weekly for 4 weeks (see section 5.1).
Slovenian: Priporočeni odmerek zdravila Truxima za ponovno samostojno zdravljenje bolnikov s folikularnim limfomom, ki so se odzvali na prejšnje samostojno zdravljenje z zdravilom Truxima po tem, ko se na predhodno zdravljenje niso odzvali ali se je pri njih bolezen ponovila, je: 375 mg/m2 telesne površine v obliki intravenske infuzije enkrat na teden 4 tedne (glejte poglavje 5.1).
English: Duration of response * Disease free survival (DFS)**
Slovenian: Preživetje brez boleznia (DFS) Analiza podskupin Preživetje brez napredovanja bolezni (PFS)
English: Truxima 100 mg concentrate for solution for infusion
Slovenian: Truxima 100 mg koncentrat za raztopino za infundiranje
English: Immunisations The safety of immunisation with live viral vaccines, following rituximab therapy has not been studied for NHL and CLL patients and vaccination with live virus vaccines is not recommended.
Slovenian: Cepljenja Varnosti imunizacije z živimi virusnimi cepivi po zdravljenju z zdravilom rituksimab pri bolnikih z NHL
English: This is because side effects can develop several months after you have had treatment.
Slovenian: Kartico pri sebi hranite še 2 leti po zadnjem odmerku zdravila Truxima, ker se lahko neželeni učinki pojavijo več mesecev po zdravljenju.
English: • indigestion, diarrhoea, acid reflux, irritation and /or ulceration of the throat and the mouth • pain in the tummy, back, muscles and/or joints
Slovenian: • nenormalni občutki v koži, kot je otrplost, mravljinčenje, zbadanje ali žarjenje, išias, migrena, omotica, izpadanje las, tesnoba, depresija, slaba prebava, driska, zgaga, vnetje in/ali razjede v žrelu in ustih, bolečina v trebuhu, hrbtu, mišicah in/ali sklepih.
English: Infusion-related reactions*
Slovenian: Hude reakcije, povezane z infuzijo (npr.
English: The MAH must ensure that all physicians who are expected to prescribe Truxima are provided with the following:
Slovenian: Imetnik dovoljenja za promet mora zagotoviti, da zdravniki, ki lahko predpišejo zdravilo Truxima, prejmejo: povzetek glavnih značilnosti zdravila, gradivo za zdravnika
English: • producing more tears, tear duct problems, inflamed eye (conjunctivitis)
Slovenian: močnejše solzenje, težave s solznimi izvodili, vnetje očesa (konjunktivitis), zvonjenje v ušesih, bolečine v ušesu,
English: log-rank p value hazard ratio (95% CI) risk reduction
Slovenian: Celokupno preživetje (mediana) vrednost p v testu log-rang razmerje ogroženosti (95-% IZ) zmanjšanje tveganja
English: Hypogammaglobulinaemia (IgG or IgM below the lower limit of normal) has been observed in RA patients treated with rituximab.
Slovenian: Laboratorijske nepravilnosti Pri bolnikih z revmatoidnim artritisom, ki so jih zdravili z rituksimabom, so opazili hipogamaglobulinemijo (IgG ali IgM pod spodnjo mejo normale).
English: Skin papilloma
Slovenian: levkocitoklastični vaskulitis
English: You will always be given Truxima as a drip (intravenous infusion).
Slovenian: Zdravilo Truxima boste dobili v intravenski infuziji.
English: • changes in blood pressure, nausea, rash, fever, feeling itchy, runny or blocked nose and sneezing, shaking, rapid heart beat, and tiredness
Slovenian: smrkav ali zamašen nos ter kihanje, drgetanje, hitro bitje srca in utrujenost, glavobol,
English: 3infusion-related reactions (hypertension, nausea, rash, pyrexia, pruritus, urticaria, throat irritation, hot flush, hypotension, rhinitis, rigors, tachycardia, fatigue, oropharyngeal pain, peripheral oedema, erythma)
Slovenian: hipotenzija, rinitis, okorelost, tahikardija, utrujenost, orofaringealna bolečina, periferni edem, eritem)
English: • abnormal sensations of the skin, such as numbness, tingling, pricking or burning,
Slovenian: kožne reakcije, kot so koprivnica, srbenje in izpuščaji,
English: Truxima 500 mg concentrate for solution for infusion Rituximab
Slovenian: Truxima 500 mg koncentrat za raztopino za infundiranje rituksimab
English: In a subgroup analysis, the ORR was higher in patients with IWF B, C, and D histological subtypes as compared to IWF A subtype (58% vs. 12%), higher in patients whose largest lesion was < 5 cm vs. > 7 cm in greatest diameter (53% vs. 38%), and higher in patients with chemosensitive relapse as compared to chemoresistant (defined as duration of response < 3 months) relapse (50% vs. 22%).
Slovenian: boljši pri bolnikih, katerih največje lezije so bile v največjem premeru manjše od 5 centimetrov (53%) kot pri bolnikih, katerih lezije so bile v največjem premeru večje kot 7 centimetrov (38%).
English: This is a type of protein called a “monoclonal antibody”.
Slovenian: Zdravilo Truxima vsebuje učinkovino rituksimab, ki je vrsta beljkovine, imenovana monoklonsko protitelo.
English: • flushing or redness of the skin
Slovenian: omotica ali občutek tesnobe,
English: The recommended dose of Truxima monotherapy used as induction treatment for adult patients with stage III-IV follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy is: 375 mg/m2 body surface area, administered as an intravenous infusion once weekly for 4 weeks.
Slovenian: IV. stadijem folikularnih limfomov, ki so neodzivni na kemoterapijo ali se je pri njih bolezen po kemoterapiji drugič ali že večkrat ponovila, je: 375 mg/m2 telesne površine v obliki intravenske infuzije enkrat na teden 4 tedne.
English: Respiratory, thoracic and mediastinal disorders bronchospasm4, respiratory disease, chest pain, dyspnoea, increased cough, rhinitis asthma, bronchiolitis obliterans, lung disorder, hypoxia interstitial lung disease7
Slovenian: Bolezni dihal, prsnega koša in mediastinalneg a prostora bronhospazem4, bolezen dihal,
English: Respiratory, thoracic and mediastinal disorders bronchospasm4 , respiratory disease, chest pain, dyspnoea, increased cough, rhinitis asthma, bronchiolitis obliterans, lung disorder, hypoxia interstitial lung disease7
Slovenian: bolečina v prsnem košu, dispneja, izrazitejši kašelj, rinitis astma, bronhiolitis obliterans,
English: p = 0.0096
Slovenian: (p = 0,0312 in p = 0,0096) (preglednica 15).
English: Description of selected adverse drug reactions
Slovenian: Opis izbranih neželenih učinkov Z infuzijo povezane z infuzijo
English: Truxima 100 mg concentrate for solution for infusion Rituximab
Slovenian: Truxima 100 mg koncentrat za raztopino za infundiranje rituksimab
English: sciatica, migraine, dizziness
Slovenian: pruritus, urtikarija, draženje žrela,
English: Truxima is indicated for the treatment of patients with moderate to severe pemphigus vulgaris (PV).
Slovenian: Zdravilo Truxima je indicirano za zdravljenje bolnikov z zmernim do hudim navadnim pemfigusom.
English: Peripheral oedema
Slovenian: +alopecija urtikarija,
English: Progression-free survival (median)
Slovenian: Preživetje brez dogodka (mediana) 38 mesecev
English: The safety of immunisation with live viral vaccines, following rituximab therapy has not been studied for NHL and CLL patients and vaccination with live virus vaccines is not recommended.
Slovenian: in KLL niso proučevali in cepljenje z živimi virusnimi cepivi ni priporočljivo.
English: Truxima
Slovenian: ZDRAVILA
English: • excess fluid retention in the face and body
Slovenian: • zvišana telesna temperatura,
English: during and after the 4 week induction course of Truxima treatment.
Slovenian: tedne pred začetkom naslednjega cikla zdravila rituksimab.
English: Number of Subjects with Major Relapse
Slovenian: Odstotek bolnikov s prvim hujšim recidivom
English: • infections of the blood (sepsis), pneumonia, shingles, cold, bronchial tube infections,
Slovenian: Pogosti neželeni učinki (pojavijo se lahko pri do 1 od 10 bolnikov): okužba krvi (sepsa), pljučnica, pasovec, prehlad, okužbe sapnic (bronhov), glivične okužbe,
English: • inflammation, irritation and / or tightness of the lungs and throat, coughing
Slovenian: zadrževanje odvečne tekočine v obrazu in telesu, vnetje, draženje in/ali stiskanje v pljučih ter v žrelu, kašljanje,
English: The European Commission issued a decision on 13 July 2010.
Slovenian: Evropska komisija je odločbo izdala dne 13. julija 2010.
English: Pierre Demolis (France)
Slovenian: Pierre Demolis (Francija)
English: Tomas Salmonson (Sweden)
Slovenian: Tomas Salmonson (Švedska)
English: Treatment should be evaluated after six to 12 months.
Slovenian: Zdravljenje je treba oceniti po šestih do 12 mesecih;
English: The company that markets these medicines is GlaxoSmithKline.
Slovenian: Družba, ki ta zdravila trži, je GlaxoSmithKline.
English: 13 July 2010
Slovenian: 13. julij 2010
English: 20 November 2008 Company responses provided on: 2 March 2009, 22 September 2009, 19 January 2010, 24 March
Slovenian: 2. marca 2009, 22. septembra 2009, 19. januarja 2010, 24. marca 2010
English: Valtrex was authorised in the EU via national procedures.
Slovenian: Zdravilo Valtrex je bilo v EU odobreno z nacionalnimi postopki.
English: Why was Valtrex reviewed?
Slovenian: Zakaj je bilo zdravilo Valtrex pregledano?
English: Valtrex is also available in the EU under other trade names: Talavir, Valaciclovir Allen, Valaciclovir Biogaran, Valaciclovir GSK, Valaciclovir Sandoz, Valaciclovir Winthrop, Valavir, Valherpes, Valtrex S, Virval and Zelitrex.
Slovenian: Zdravilo Valtrex je v EU na voljo tudi pod drugimi imeni: Talavir, Valaciclovir Allen, Valaciclovir Biogaran, Valaciclovir GSK, Valaciclovir Sandoz, Valaciclovir Winthrop, Valavir, Valherpes, Valtrex S, Virval in Zelitrex.
English: The European Medicines Agency has completed a review of Valtrex and associated names.
Slovenian: Evropska agencija za zdravila je zaključila pregled zdravila Valtrex in povezanih imen.
English: For recurrent episodes treatment should be for three to five days.
Slovenian: Zdravljenje ponovitev mora trajati od tri do pet dni.
English: The areas harmonised include: 4.1 Therapeutic indications The CHMP recommended that Valtrex should be used for:
Slovenian: Področja, ki jih je treba uskladiti, so: 4.1 Terapevtske indikacije CHMP je priporočil, da se zdravilo Valtrex uporablja za:
English: The CHMP recommended that Valtrex should only be used in pregnancy if the potential benefits of treatment outweigh the risks.
Slovenian: CHMP je priporočil, da se lahko zdravilo Valtrex med nosečnostjo uporablja le, če so morebitne koristi zdravljenja večje od tveganja.
English: This has led to divergences across Member States in the way the medicine can be used, as seen in the differences in the summaries of product characteristics (SmPCs), labelling and package leaflets in the countries where the medicine is marketed.
Slovenian: To je v državah članicah privedlo do razhajanj glede uporabe zdravila, kakor je razvidno iz povzetkov glavnih značilnosti zdravila, označevanja in navodil za uporabo v državah, v katerih je zdravilo v prometu.
English: What is Valtrex?
Slovenian: Kaj je zdravilo Valtrex?
English: Cytomegalovirus can cause harmful effects in high-risk populations such as infants and patients who have had a solid organ transplant.
Slovenian: Citomegalovirus lahko škoduje populacijam z velikim tveganjem, kot so dojenčki in bolniki po presaditvi čvrstega organa.
English: Immunocompromised patients should be treated for a further two days after the crusting of their lesions.
Slovenian: Pri imunsko kompromitiranih bolnikih mora zdravljenje trajati še dva dni po oblikovanju krast na lezijah.
English: The Committee recommended that the doses of Valtrex should be reduced in patients with impaired kidney function.
Slovenian: Odbor je priporočil, da se odmerki zdravila Valtrex zmanjšajo za bolnike z okvarjenim delovanjem ledvic.
English: • the prevention of cytomegalovirus infection and disease following solid organ transplantation in adults and adolescents.
Slovenian: • preprečevanje okužbe s citomegalovirusom in citomegalovirusne bolezni po presaditvi čvrstega organa pri odraslih bolnikih in mladostnikih.
English: Valtrex is also used to prevent infection with cytomegalovirus.
Slovenian: Zdravilo Valtrex se uporablja tudi za preprečevanje okužbe s citomegalovirusom.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) has concluded that there is a need to harmonise the prescribing information for Valtrex in the European Union (EU).
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da je treba v Evropski uniji (EU) uskladiti podatke o predpisovanju zdravila Valtrex.
English: It is used to treat infections with herpes, including varicella zoster which causes shingles and herpes simplex viruses (HSV) which can cause cold sores or genital herpes.
Slovenian: Uporablja se za zdravljenje okužbe z virusi herpesa, vključno z virusom varicella zoster, ki povzroča pasovec, in virusom herpes simplex (HSV), ki lahko povzroči kožne mehurčke ali genitalni herpes.
English: The Committee also harmonised other sections of the SmPC, including the sections on special warnings and side effects.
Slovenian: Odbor je uskladil tudi druga poglavja povzetka glavnih značilnosti zdravila, vključno z razdelkoma o posebnih opozorilih in neželenih učinkih.
English: • HSV infections of the skin and mucous membranes including: the treatment of the first episode of genital herpes in immunocompetent patients; the treatment of recurrent episodes of genital herpes in immunocompetent and immunocompromised patients (patients with a weakened immune system); the suppression of the recurrence of genital herpes in immunocompetent and immunocompromised patients; treatment of herpes labialis (cold sores); the treatment and suppression of recurrent ocular (eye) HSV infection;
Slovenian: • okužbe s HSV na koži in sluznici, vključno z: zdravljenjem prvega pojava genitalnega herpesa pri imunsko kompetentnih bolnikih; zdravljenjem ponovitev genitalnega herpesa pri imunsko kompetentnih in imunsko kompromitiranih bolnikih (bolnikih z oslabljenim imunskim sistemom); supresijo ponovitve genitalnega herpesa pri imunsko kompetentnih in imunsko kompromitiranih bolnikih; zdravljenjem labialnega herpesa; zdravljenjem in supresijo ponovitev očesnih okužb s HSV;
English: The CHMP recommended that Valtrex should not be used in people who may be hypersensitive (allergic) to valaciclovir, aciclovir or to any of the excipients.
Slovenian: CHMP je priporočil, da zdravila Valtrex ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) valaciklovir, aciklovir ali katero koli pomožno snov zdravila.
English: 4.2 Posology and method of administration The Committee harmonised the doses of Valtrex to be used for the different conditions.
Slovenian: 4.2 Odmerjanje in način uporabe Odbor je uskladil odmerke zdravila Valtrex za uporabo v različnih okoliščinah.
English: 500 mg once a day for suppressing the recurrence of HSV infections in immunocompetent adults and 500 mg twice daily in immunocompromised adults.
Slovenian: 500 mg enkrat na dan za supresijo ponovitve okužbe s HSV pri imunsko kompetentnih odraslih bolnikih in 500 mg dvakrat na dan za imunsko kompromitirane odrasle bolnike.
English: Aciclovir is an antiviral that works by blocking an enzyme that the viruses need to produce DNA.
Slovenian: Aciklovir je protivirusna snov, ki deluje z zaviranjem encima, ki ga virusi potrebujejo za tvorbo DNK.
English: Valtrex is an antiviral medicine that contains the active substance valaciclovir.
Slovenian: Valtrex je protivirusno zdravilo, ki vsebuje zdravilno učinkovino valaciklovir.
English: The active substance in Valtrex, valaciclovir, is broken down in the body into two substances, aciclovir and valine (an amino-acid).
Slovenian: Zdravilna učinkovina v zdravilu Valtrex, valaciklovir, se v človeškem telesu razgradi v dve spojini: aciklovir in valin (aminokislino).
English: • For the prevention of cytomegalovirus infection following organ transplantation in adults and adolescents, the recommended dosage is 2000 mg four times a day, to be started as early as possible after the transplant.
Slovenian: • Za preprečevanje citomegalovirusne okužbe po presaditvi organa pri odraslih bolnikih in mladostnikih je priporočeno odmerjanje 2 000 mg štirikrat na dan, ki se začne čim prej po presaditvi.
English: • the treatment of herpes zoster in adults with mild or moderate immunosuppression (reduced activity of the immune system);
Slovenian: • zdravljenje herpesa zostra pri odraslih bolnikih z blago ali zmerno imunsko supresijo (z zmanjšanim delovanjem imunskega sistema);
English: It should also be used with caution during breast-feeding.
Slovenian: Zdravilo Valtrex je treba previdno uporabljati tudi med dojenjem.
English: • the treatment of herpes zoster (shingles) and ophthalmic zoster (shingles around the eye) in immunocompetent adults (patients with an immune system that works normally);
Slovenian: • zdravljenje herpesa zostra (pasovca) in očesnega herpesa zostra (pasovca okoli oči) pri imunsko kompetentnih odraslih osebah (bolnikih, pri katerih imunski sistem deluje normalno);
English: • For use in HSV infections of the skin and mucous membranes, the following doses are recommended: 500 mg twice a day for treating immunocompetent patients.
Slovenian: • Priporočeni odmerki za okužbe s HSV na koži in sluznici so naslednji: 500 mg dvakrat na dan za zdravljenje imunsko kompetentnih bolnikov.
English: On 22 October 2008, the European Commission referred the matter to the CHMP in order to harmonise the marketing authorisations for Valtrex and associated names in the EU.
Slovenian: Da bi Evropska komisija uskladila dovoljenja za promet z zdravilom Valtrex in povezanih imen v EU, je dne 22. oktobra 2008 zadevo napotila na CHMP.
English: • For the treatment of herpes zoster, the recommended dose is 1000 mg three times a day for seven days in immunocompetent adults.
Slovenian: • Priporočeni odmerek za zdravljenje herpesa zostra pri imunsko kompetentnih odraslih bolnikih je 1 000 mg trikrat na dan skupno sedem dni.
English: Valtrex was identified as needing harmonisation by the Co-ordination Group on the Mutual and Decentralised Procedures - Human (CMD(h)).
Slovenian: Skupina za usklajevanje za postopek z medsebojnim priznavanjem in decentralizirani postopek za zdravila za uporabo v humani medicini (CMD(h)) je ugotovila, da je za zdravilo Valtrex potrebno usklajevanje.
English: 1,000 mg twice a day for at least five days for treating immunocompromised patients.
Slovenian: Pri prvih epizodah, ki so lahko hujše, se lahko zdravljenje podaljša na deset dni; 2 000 mg dvakrat na dan skupno en dan za zdravljenje bolnikov z labialnim herpesom: 1 000 mg dvakrat na dan skupno vsaj pet dni za zdravljenje imunsko kompromitiranih bolnikov;
English: Therefore, contact with skin or eyes should be avoided.
Slovenian: Zato je treba stik s kožo ali očmi preprečiti.
English: The full EPAR for Zactran can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila Zactran je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
English: The European Commission granted a marketing authorisation valid throughout the EU for Zactran on 24 July 2008.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Zactran, veljavno po vsej Evropski uniji, izdala 24. julija 2008.
English: The main measures of effectiveness were respiratory and depression scores as well as body temperature.
Slovenian: Glavna merila učinkovitosti so bila dihanje, izčrpanost in telesna temperatura.
English: This is a summary of the European public assessment report (EPAR) for Zactran.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Zactran.
English: It is not intended to provide practical advice on how to use Zactran.
Slovenian: Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
English: Zactran gamithromycin
Slovenian: Zactran gamitromicin
English: Cattle weighing more than 250 kg, and pigs and sheep weighing more than 125 kg, will need to have the dose divided and injected at more than one site.
Slovenian: Pri govedu, ki tehta več kot 250 kg, ter prašičih in ovcah, ki tehtajo več kot 125 kg, bo treba odmerek razdeliti in ga injicirati na različnih mestih.
English: What benefits of Zactran have been shown in studies?
Slovenian: Kakšne koristi je zdravilo Zactran izkazalo v študijah?
English: The Agency's Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Zactran's benefits are greater than its risks and recommended that it be approved for use in the EU.
Slovenian: Odbor za zdravila za uporabo v veterinarski medicini (CVMP) pri agenciji je zaključil, da so koristi zdravila Zactran večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
English: These local reactions are short-lived and typically resolve within 2 days for pigs and 4 days for sheep.
Slovenian: Tovrstne lokalne reakcije so kratkotrajne in običajno izzvenijo v dveh dneh pri prašičih in štirih dneh pri ovcah.
English: Antibiotic resistance is the ability of bacteria to grow in the presence of an antibiotic that would normally kill them or limit their growth.
Slovenian: S pridobitvijo odpornosti proti antibiotikom dobijo bakterije sposobnost rasti kljub prisotnosti antibiotika, ki bi jih sicer običajno uničil ali omejil njihovo rast.
English: It works by blocking the bacteria's ribosomes, which are parts of the cells where proteins are produced, and so prevents the bacteria from growing.
Slovenian: Deluje tako, da zavira ribosome bakterij, tj. dele celic, na katerih poteka tvorba beljakovin, in tako preprečuje rast bakterij.
English: What are the risks associated with Zactran?
Slovenian: Kakšna tveganja so povezana z zdravilom Zactran?
English: Why is Zactran approved?
Slovenian: Zakaj je bilo zdravilo Zactran odobreno?
English: Other information about Zactran
Slovenian: Druge informacije o zdravilu Zactran